CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 13 enrolled
Drug / intervention
Buprenorphine +1 moredrug
Likely dose
Buprenorphine 0.2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01407575
NCT01407575Phase 3Completed
CompareCT.gov

Buprenorphine For Treatment Resistant Depression

University of Pittsburgh·interventional·Posted Aug 2, 2011·Updated Mar 9, 2018

In Brief

A Phase 3 clinical trial evaluating Buprenorphine and Placebo for Depression and 2 related conditions. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Depressive Disorder, Depressive Disorder, Major
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2, 2011
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.9 years ago

Interventions

Buprenorphinedrug

low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)

Placebodrug

matched placebo